@article{10.37349/eaa.2025.100984,
abstract = {Over 330 million people globally have asthma, a chronic disease with multiple endotypes and observable phenotypes. This disease has a substantial socioeconomic impact. A thorough assessment of multiple clinical aspects (such as the presence of atopy, comorbidities, and clinical presentations), characteristics of lung function (such as the degree of bronchial reversibility, the involvement of the airway obstruction, and airway hyperreactivity), and the interaction of sputum and systemic inflammatory factors (such as neutrophilic, eosinophilic, and mixed) are required to determine the specific endotypes of asthma. The precision medicine approach to asthma represents a new paradigm, with improved opportunities for more effective and appropriate personalized therapies and new insights into the immunological aspects of asthma that demand further research. In the world of precision medicine, biomarker-based therapies for individual patients are just the beginning of an exciting and emerging journey in allergy treatment. A collection of biomarkers might be utilized to define and classify the endotypes based on the phenotyping of asthma, which will be more likely with omics information and unbiased clustering. This review will contribute to the development of personalized therapy for asthma, enabling more accurate treatment. It will also serve as a source of novel targets and new treatments for every identified endotype.},
author = {Muzaffar, Nadia and Baber, Muhammad and Iqra Malik, Hafiza},
doi = {10.37349/eaa.2025.100984},
journal = {Exploration of Asthma & Allergy},
elocation-id = {100984},
title = {Role of precision medicine on different endotypes of asthma},
url = {https://www.explorationpub.com/Journals/eaa/Article/100984},
volume = {3},
year = {2025}
}